trending Market Intelligence /marketintelligence/en/news-insights/trending/dcfmpuq9uttpvhyryeshnw2 content esgSubNav
In This List

Oncobiologics names board member

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Oncobiologics names board member

Cranbury, N.J.-based Oncobiologics Inc. appointed Joerg Windisch to its board, replacing Yezan Haddadin who resigned.

Windisch, a nominee of Oncobiologics shareholder GMS Tenshi Holdings Pte. Ltd., is COO of Polish biotechnology company Polpharma Biologics. He has worked at Sandoz Biopharmaceuticals for two decades, most recently as chief science officer.

"Joerg is an experienced industry executive and scientist with over 20 years in the development of biological therapeutics. His broad expertise in biosimilar development, manufacturing and regulatory affairs will support our work in further developing our biosimilar product candidate pipeline in the years ahead," Oncobiologics Chairman and CEO Pankaj Mohan said in a statement.

Sandoz Inc. is a Novartis AG unit.